Adult-use cannabis policy stages linked to lower heroin involvement in…

From medical authorization to adult-use retail: Cannabis policy stages and heroin involvement among U.S. substance use treatment admissions.

The International journal on drug policy • • Highly Relevant
🤖

AI Summary

This observational policy study asked whether heroin involvement differed across successive cannabis-policy stages among U.S. substance-use treatment admissions. It analyzed approximately 55.2 million admission records from 1992 through 2023, comparing state-year policy regimes with continued absence of a coded cannabis policy using a staggered-adoption difference-in-differences design. The primary outcome was heroin involvement among reported admissions—not heroin use in the general population.

In the primary equal-state analysis, heroin involvement was lower during adult-use legalization without operational retail and during operational adult-use retail than under continued no-policy status. The estimated differences were reported per 1,000 admissions; medical-policy stages showed no statistically significant heroin-related effects, and estimates for other opiates and synthetics were also not statistically significant. The later-stage heroin estimates remained negative but were attenuated and no longer statistically significant with equal-state-year weighting. Because this is an observational analysis of treatment admissions, it cannot establish that cannabis-policy changes caused the differences or that heroin use declined overall; this is an abstract-based summary.

💡 Key Findings

1
In the primary equal-state analysis, any heroin involvement was lower during adult-use legalization without operational retail and operational adult-use retail, relative to continued no-policy status.
High
80%
2
The corresponding primary-heroin estimates were also negative and statistically significant in the primary analysis; estimates were reported per 1,000 reported admissions.
High
80%
3
Heroin-related estimates were not statistically significant during medical-policy stages; estimates for other opiates and synthetics were also non-significant.
High
90%
4
Later-stage heroin estimates remained negative but were attenuated and statistically non-significant under equal-state-year weighting.
High
90%

📄 Original Abstract

INTRODUCTION: Evidence linking cannabis-policy liberalization to opioid outcomes is inconsistent, and the accumulation of successive policy stages has received limited attention. We estimated differences in opioid involvement among reported substance use treatment admissions across an accumulated cannabis-policy pathway distinguishing legal authorization, operational access, and preceding policy history. METHODS: Data were drawn from approximately 55.2 million admission records in the Treatment Episode Data Set-Admissions covering 1992 through 2023. Cannabis policy was classified into five mutually exclusive state-year regimes: no coded cannabis policy, medical authorization without operational sales, operational medical access, adult-use legalization without operational retail, and operational adult-use retail. A staggered-adoption difference-in-differences design estimated regime-specific average treatment effects on the treated (ATTs), representing accumulated pathway effects relative to continued no-policy status. Event-time and equal-state-year analyses assessed temporal patterns and sensitivity to alternative weighting. RESULTS: In the primary equal-state analysis, heroin-related ATTs were not statistically significant during medical-policy stages. Any heroin involvement was lower during adult-use legalization without operational retail (ATT = -107.01 per 1000 reported admissions; 95% confidence interval [CI] = -190.91 to -23.12) and operational adult-use retail (ATT = -127.71; 95% CI = -225.80 to -29.63). Corresponding primary-heroin ATTs were -102.81 (95% CI = -182.39 to -23.24) and -126.45 (95% CI = -221.47 to -31.44), respectively. Estimates for other opiates and synthetics were statistically non-significant. Later-stage heroin estimates remained negative but were attenuated and statistically non-significant under equal-state-year weighting. CONCLUSION: The accumulated-pathway framework identified lower heroin involvement during both adult-use policy environments relative to continued no-policy status in the primary analysis. The findings demonstrate the value of distinguishing successive policy environments and interpreting later-stage effects in the context of preceding policy history.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.